Arrowhead reports strong early sales for newly approved cholesterol drug

Arrowhead Pharmaceuticals reported fiscal second-quarter 2026 results and detailed early commercial progress for REDEMPLO (plozasiran), its siRNA therapy for familial chylomicronemia syndrome, which the U.S. Food and Drug Administration approved on 18 November 2025. The company reported more than 40…